Free Trial
TSE:TRIL

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

Trillium Therapeutics logo

About Trillium Therapeutics Stock (TSE:TRIL)

Key Stats

Today's Range
N/A
50-Day Range
C$23.33
C$23.33
52-Week Range
N/A
Volume
60,423 shs
Average Volume
166,586 shs
Market Capitalization
C$2.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRIL Stock News Headlines

SYRE Spyre Therapeutics, Inc.
Elon knows the truth, which is why they want him silenced
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration.
See More Headlines

TRIL Stock Analysis - Frequently Asked Questions

Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include NVIDIA (NVDA), Toronto-Dominion Bank (TD), Meta Platforms (META), Moderna (MRNA), Shopify (SHOP), Tesla (TSLA) and Bank of Nova Scotia (BNS).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$43,000.00
Book Value
C$2.17 per share

Miscellaneous

Free Float
N/A
Market Cap
C$2.45 billion
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (TSE:TRIL) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners